266 related articles for article (PubMed ID: 18089795)
21. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
[TBL] [Abstract][Full Text] [Related]
22. Sca-1 / c-Kit receptor expression and apoptosis pattern in ENU induced MDS mice.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2009; 4(4):229-41. PubMed ID: 20720596
[TBL] [Abstract][Full Text] [Related]
23. Nuclear phospholipase C beta1, regulation of the cell cycle and progression of acute myeloid leukemia.
Cocco L; Manzoli L; Palka G; Martelli AM
Adv Enzyme Regul; 2005; 45():126-35. PubMed ID: 16024064
[TBL] [Abstract][Full Text] [Related]
24. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
[TBL] [Abstract][Full Text] [Related]
25. Myelodysplastic syndrome associated with monosomy 7 in childhood: a retrospective study.
Aktas D; Tuncbilek E
Cancer Genet Cytogenet; 2006 Nov; 171(1):72-5. PubMed ID: 17074595
[TBL] [Abstract][Full Text] [Related]
26. Expression of p53, bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes.
Invernizzi R; Pecci A; Bellotti L; Ascari E
Leuk Lymphoma; 2001 Jul; 42(3):481-9. PubMed ID: 11699413
[TBL] [Abstract][Full Text] [Related]
27. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?
Hake CR; Graubert TA; Fenske TS
Bone Marrow Transplant; 2007 Jan; 39(2):59-70. PubMed ID: 17143301
[TBL] [Abstract][Full Text] [Related]
28. Mouse model for NRAS-induced leukemogenesis.
Parikh C; Ren R
Methods Enzymol; 2008; 439():15-24. PubMed ID: 18374153
[TBL] [Abstract][Full Text] [Related]
29. Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology.
Disperati P; Ichim CV; Tkachuk D; Chun K; Schuh AC; Wells RA
Leuk Res; 2006 Feb; 30(2):233-9. PubMed ID: 16046234
[TBL] [Abstract][Full Text] [Related]
30. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
Swolin B; Rödjer S; Westin J
Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
[TBL] [Abstract][Full Text] [Related]
31. Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas.
Wolf S; Rudolph C; Morgan M; Büsche G; Salguero G; Stripecke R; Schlegelberger B; Baum C; Modlich U
Oncogene; 2013 Jun; 32(25):3028-38. PubMed ID: 22847614
[TBL] [Abstract][Full Text] [Related]
32. RAS and the myelodysplastic syndromes.
Gallagher A; Darley R; Padua RA
Pathol Biol (Paris); 1997 Sep; 45(7):561-8. PubMed ID: 9404480
[TBL] [Abstract][Full Text] [Related]
33. Many are called MDS cell lines: one is chosen.
Drexler HG; Dirks WG; Macleod RA
Leuk Res; 2009 Aug; 33(8):1011-6. PubMed ID: 19344951
[TBL] [Abstract][Full Text] [Related]
34. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia.
Pinheiro RF; de Sá Moreira E; Silva MR; Alberto FL; Chauffaille Mde L
Cancer Genet Cytogenet; 2008 Jun; 183(2):89-93. PubMed ID: 18503825
[TBL] [Abstract][Full Text] [Related]
35. Nuclear inositide signaling in myelodysplastic syndromes.
Follo MY; Mongiorgi S; Finelli C; Clissa C; Ramazzotti G; Fiume R; Faenza I; Manzoli L; Martelli AM; Cocco L
J Cell Biochem; 2010 Apr; 109(6):1065-71. PubMed ID: 20058233
[TBL] [Abstract][Full Text] [Related]
36. Analysis of immunohistochemical results of the ras oncogene product p21 in myelodysplastic syndromes.
Kalmantis T; Kalmanti M; Vassilaki M; Spandidos DA
Anticancer Res; 1993; 13(4):1103-6. PubMed ID: 8352532
[TBL] [Abstract][Full Text] [Related]
37. [Preliminary study of biological characteristics of myelodysplastic syndromes clonal cells].
Li X; Wu LY; Ying SX; Chang CK; He Q; Song LQ; Pu Q
Zhonghua Xue Ye Xue Za Zhi; 2007 Jul; 28(7):478-83. PubMed ID: 18072633
[TBL] [Abstract][Full Text] [Related]
38. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
Braun T; Fenaux P
Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
[TBL] [Abstract][Full Text] [Related]
39. Transgenic mice expressing the p75 CCAAT-displacement protein/Cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia.
Cadieux C; Fournier S; Peterson AC; Bédard C; Bedell BJ; Nepveu A
Cancer Res; 2006 Oct; 66(19):9492-501. PubMed ID: 17018605
[TBL] [Abstract][Full Text] [Related]
40. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.
Rajapaksa R; Ginzton N; Rott LS; Greenberg PL
Blood; 1996 Dec; 88(11):4275-87. PubMed ID: 8943864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
